MCID: ISC004
MIFTS: 62

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases

Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 55 44 15 17 72
Acute Coronary Syndrome 72

Classifications:



External Ids:

Disease Ontology 12 DOID:326
MeSH 44 D007511
NCIt 50 C34738
SNOMED-CT 68 52674009
UMLS 72 C0022116 C0948089

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to retinal ischemia and limb ischemia, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is ENSG00000278514 (), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Fenoldopam and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and liver, and related phenotypes are cardiovascular system and cellular

Wikipedia : 75 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1546)
# Related Disease Score Top Affiliating Genes
1 retinal ischemia 35.1 VEGFA CXCL12 CASP3
2 limb ischemia 35.0 VEGFA NOS3 CXCL12 ACE
3 coronary artery anomaly 33.7 PON1 NOS3 GJA1 ACE
4 vascular disease 33.5 VEGFA PON1 NOS3 HMOX1 ACE
5 microvascular complications of diabetes 5 33.1 VEGFA PON1 NOS3 ACE
6 myocardial infarction 32.7 VEGFA PON1 NOS3 GJA1 CXCL12 CASP3
7 arteries, anomalies of 32.2 VEGFA PON1 NOS3 ACE
8 peripheral artery disease 32.0 VEGFA NOS3 ACE
9 pulmonary edema 31.7 NOS3 HMOX1 ACE
10 stroke, ischemic 31.5 PON1 NOS3 CASP3 ACE
11 vascular dementia 31.5 VEGFA PON1 ACE
12 retinal artery occlusion 31.4 VEGFA HMOX1 ACE
13 diabetic neuropathy 31.4 VEGFA SOD2 EPO ACE
14 renovascular hypertension 31.2 NOS3 HMOX1 ACE
15 coronary heart disease 1 31.1 PON1 NOS3 ACE
16 heart disease 31.1 VEGFA PON1 NOS3 GJA1 ACE
17 diabetes mellitus 31.1 VEGFA SOD2 PON1 NOS3 EPO ACE
18 nervous system disease 30.6 VEGFA CDK5 CASP3 ACE
19 myeloma, multiple 30.5 VEGFA EPO CXCL12 CASP9 CASP3
20 varicocele 30.4 NOS3 CASP9 CASP3
21 hepatopulmonary syndrome 30.4 VEGFA NOS3 HMOX1
22 hypertensive encephalopathy 30.1 EPO ACE
23 parkinson disease, late-onset 30.1 SOD2 HMOX1 CDK5 CASP9 CASP3
24 nasopharyngeal carcinoma 30.0 VEGFA CXCL12 CASP9 CASP3
25 transient cerebral ischemia 12.7
26 chronic intestinal vascular insufficiency 11.7
27 hypoxia 11.6
28 cerebral hypoxia 11.6
29 nonarteritic anterior ischemic optic neuropathy 11.5
30 vertebrobasilar insufficiency 11.5
31 arterial calcification, generalized, of infancy, 1 11.5
32 legg-calve-perthes disease 11.5
33 sturge-weber syndrome 11.5
34 lateral medullary syndrome 11.5
35 myocardial stunning 11.4
36 volkmann contracture 11.4
37 ischemic colitis 11.4
38 peritonitis 11.4
39 short bowel syndrome 11.4
40 respiratory failure 11.4
41 fibromuscular dysplasia 11.4
42 polyarteritis nodosa 11.4
43 exudative vitreoretinopathy 1 11.4
44 raynaud disease 11.4
45 microvascular complications of diabetes 1 11.4
46 microvascular complications of diabetes 2 11.4
47 central retinal vein occlusion 11.4
48 microvascular complications of diabetes 3 11.3
49 microvascular complications of diabetes 4 11.3
50 microvascular complications of diabetes 6 11.3

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


muscle weakness, polydipsia, angina pectoris, anoxemia

MGI Mouse Phenotypes related to Ischemia:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
2 cellular MP:0005384 10.42 CASP3 CASP9 CXCL12 EGR1 EPO GJA1
3 homeostasis/metabolism MP:0005376 10.37 ACE ADORA3 CASP3 CDK5 EGR1 EPO
4 behavior/neurological MP:0005386 10.35 ACE ADORA3 CASP3 CDK5 EGR1 GJA1
5 hematopoietic system MP:0005397 10.32 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
6 immune system MP:0005387 10.29 ACE ADORA3 CASP3 CASP9 CXCL12 EGR1
7 growth/size/body region MP:0005378 10.26 ACE CASP3 CASP9 EGR1 GJA1 HMOX1
8 mortality/aging MP:0010768 10.25 ACE CASP3 CASP9 CDK5 CXCL12 EGR1
9 endocrine/exocrine gland MP:0005379 10.19 ACE CASP3 CASP9 EGR1 GJA1 HMOX1
10 nervous system MP:0003631 10.1 CASP3 CASP9 CDK5 CXCL12 EGR1 GJA1
11 muscle MP:0005369 10.07 CASP3 CXCL12 EPO GJA1 HMOX1 NOL3
12 integument MP:0010771 10.06 ADORA3 CASP3 CDK5 EGR1 EPO GJA1
13 liver/biliary system MP:0005370 10.03 ACE CXCL12 EGR1 EPO HMOX1 NOS3
14 renal/urinary system MP:0005367 9.86 ACE ADORA3 CASP3 HMOX1 NOS3 PRKAA2
15 reproductive system MP:0005389 9.85 ACE CASP3 CXCL12 EGR1 GJA1 HMOX1
16 respiratory system MP:0005388 9.7 ADORA3 CASP3 CASP9 CDK5 EGR1 EPO
17 vision/eye MP:0005391 9.23 ADORA3 CASP3 EGR1 GJA1 NOS3 REST

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1077)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
2
Promethazine Approved, Investigational Phase 4 60-87-7 4927
3
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
4
Zolpidem Approved Phase 4 82626-48-0 5732
5
Capsaicin Approved Phase 4 404-86-4 1548943
6
Gliclazide Approved Phase 4 21187-98-4 3475
7
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
8
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
9
Nadroparin Approved, Investigational Phase 4
10
Pravastatin Approved Phase 4 81093-37-0 54687
11
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
12
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
13
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
14
Famotidine Approved Phase 4 76824-35-6 3325
15
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
16
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
17
Warfarin Approved Phase 4 81-81-2 6691 54678486
18
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Fondaparinux Approved, Investigational Phase 4 104993-28-4
21
Glucagon Approved Phase 4 16941-32-5
22
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
23
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
24
Sodium citrate Approved, Investigational Phase 4 68-04-2
25
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
26
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
27
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
28
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
29
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
30
Caffeine Approved Phase 4 58-08-2 2519
31
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
32
Insulin Lispro Approved Phase 4 133107-64-9
33
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
34
Saxagliptin Approved Phase 4 361442-04-8 11243969
35 Hydrotalcite Approved, Experimental, Investigational Phase 4 12304-65-3
36
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
37
Sucralfate Approved Phase 4 54182-58-0
38
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
39
Amlodipine Approved Phase 4 88150-42-9 2162
40
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
41
Eplerenone Approved Phase 4 107724-20-9 150310 443872
42
Digoxin Approved Phase 4 20830-75-5 30322 2724385
43
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
44
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
45
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
46
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
47
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
48
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
49
Remifentanil Approved Phase 4 132875-61-7 60815
50
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693

Interventional clinical trials:

(show top 50) (show all 8464)
# Name Status NCT ID Phase Drugs
1 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
2 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
3 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
4 Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome Unknown status NCT01245803 Phase 4 additional rosuvastatin loading;placebo control
5 Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial. Unknown status NCT01572129 Phase 4 Clopidogrel;Placebo
6 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4 Varenicline 100 mg by mouth twice daily;control
7 Nanjing First Hospital, Nanjing Medical University Unknown status NCT01171911 Phase 4 Nicardipine , Esmolol
8 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
9 Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Unknown status NCT01906749 Phase 4 Colchicine;Placebo
10 Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist Unknown status NCT02627521 Phase 4 Ticagrelor
11 OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™ Unknown status NCT00914420 Phase 4
12 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
13 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
14 Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS) Unknown status NCT02592720 Phase 4 cocktail
15 Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial Unknown status NCT01690832 Phase 4 standard saline infusion;fenoldopam infusion
16 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
17 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
18 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
19 Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome Unknown status NCT02809820 Phase 4 Carvedilol;Metoprolol
20 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
21 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques. Unknown status NCT01773512 Phase 4 Rosuvastatin
22 Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention Unknown status NCT01040936 Phase 4 Atorvastatin;Atorvastatin
23 SWITCH 600/60: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel Unknown status NCT01365221 Phase 4 Prasugrel;Prasugrel
24 Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
25 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
26 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
27 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
28 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
29 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
30 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
31 An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI(EARLY-MYO II) Unknown status NCT02201667 Phase 4 Ticagrelor;clopidogrel;Aspirin
32 A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS Unknown status NCT02284503 Phase 4 Rosuvastatin
33 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
34 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
35 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" Unknown status NCT02028234 Phase 4 Pantoprazole,;Omeprazole
36 Randomized Controlled Study of a Rapid "Rule Out" Strategy Using CT Coronary Angiogram Versus Traditional Care for Low- to Intermediate-Risk ED Patients With Potential Acute Coronary Syndromes Unknown status NCT00933400 Phase 4
37 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
38 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
39 Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome Unknown status NCT02379676 Phase 4 Ticagrelor;Clopidogrel
40 A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Bio-active-stent (BAS) Stent and SYNERGY™ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography Unknown status NCT02464397 Phase 4
41 Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
42 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
43 Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study Unknown status NCT01955200 Phase 4 Ticagrelor;Clopidogrel;Cilostazol;Clopidogrel;Clopidogrel
44 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
45 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
46 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
47 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
48 Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
49 MICROS-Pilot Study Microcirculation In Acute Coronary Syndromes; Effect of Pre-treatment of High Dose Rosuvastatin on Coronary Microcirculation in Primary PCI Unknown status NCT01382472 Phase 4 Rosuvastatin;Simvastatin
50 Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing Unknown status NCT01477775 Phase 4 Oral P2Y12 receptor blocker;Customized choice for the oral P2Y12 receptor blocker

Search NIH Clinical Center for Ischemia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylsalicylic acid
Bivalirudin
Captopril
Clopidogrel
Enoxaparin
Eptifibatide
Warfarin

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

41
Heart, Brain, Liver, Endothelial, Kidney, Testes, Lung

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 50989)
# Title Authors PMID Year
1
Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 9 38
20235222 2010
2
Ischemia induces endoplasmic reticulum stress and cell apoptosis in human brain. 9 38
20347937 2010
3
Vascular responses to hypoxia and ischemia. 9 38
19729615 2010
4
Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. 9 38
20138968 2010
5
Loss of clusterin expression worsens renal ischemia-reperfusion injury. 9 38
20007348 2010
6
Effects of AMP-activated protein kinase in cerebral ischemia. 9 38
20010958 2010
7
Heme oxygenase-1 protects donor livers from ischemia/reperfusion injury: the role of Kupffer cells. 9 38
20222175 2010
8
Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. 9 38
20152804 2010
9
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. 9 38
20133634 2010
10
A highlight of myoglobin diversity: the nitrite reductase activity during myocardial ischemia-reperfusion. 9 38
19836457 2010
11
Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. 9 38
20190407 2010
12
Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. 9 38
19920350 2009
13
Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. 9 38
19850943 2009
14
Allopurinol, xanthine oxidase, and cardiac ischemia. 9 38
19794315 2009
15
Low-density lipoproteins oxidized after intestinal ischemia/reperfusion in rats. 9 38
19482302 2009
16
Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. 9 38
19917352 2009
17
Association of cystatin C with ischemia in patients with coronary heart disease. 9 38
19816865 2009
18
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. 9 38
19576596 2009
19
Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. 9 38
19622751 2009
20
Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. 9 38
19682205 2009
21
Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. 9 38
19344900 2009
22
Lentiviral-mediated overexpression of Bcl-xL protects primary endothelial cells from ischemia/reperfusion injury-induced apoptosis. 9 38
19716047 2009
23
Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. 9 38
19753114 2009
24
Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. 9 38
19498441 2009
25
Increased expression of monocarboxylate transporter 1 after acute ischemia of isolated, perfused mouse hearts. 9 38
19604494 2009
26
N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. 9 38
19685518 2009
27
Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. 9 38
19596001 2009
28
Use of changes in B-type natriuretic peptides to detect ischemia in selected patients. 9 38
18632168 2009
29
The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. 9 38
19443639 2009
30
Adrenomedullin ameliorates ischemia reperfusion injury in rat livers. 9 38
19663270 2009
31
Dietary sources of nitrite as a modulator of ischemia/reperfusion injury. 9 38
19212422 2009
32
Ischemia/reperfusion Lung Injury Increases Serum Ferritin and Heme Oxygenase-1 in Rats. 9 38
19885035 2009
33
The neuronal apoptotic death in global cerebral ischemia in gerbil: important role for sodium channel modulator. 9 38
19115407 2009
34
Angiopoietin-1 in the treatment of ischemia and sepsis. 9 38
18791498 2009
35
Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. 9 38
19456402 2009
36
Circulating biochemical markers of brain damage in infants complicated by ischemia reperfusion injury. 9 38
19355873 2009
37
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. 9 38
19371824 2009
38
Neutrophil elastase inhibitor attenuates hippocampal neuronal damage after transient forebrain ischemia in rats. 9 38
19168036 2009
39
Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. 9 38
19094989 2009
40
Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 9 38
19279473 2009
41
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. 9 38
19075097 2009
42
[Biochemical markers in the diagnosis of acute coronary syndrome]. 9 38
19681456 2009
43
FAK regulates cardiomyocyte survival following ischemia/reperfusion. 9 38
19028502 2009
44
Regulation of cardiac afferent excitability in ischemia. 9 38
19655108 2009
45
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. 9 38
18812468 2009
46
Effect of ischemia/reperfusion on bladder nerve and detrusor cell damage. 9 38
18998234 2009
47
Ischemia alters the expression of connexins in the aged human brain. 9 38
19794823 2009
48
Ischemia-induced up-regulation of heme oxygenase-1 protects from apoptotic cell death and tissue necrosis. 9 38
18262556 2008
49
Pretreatment with bone morphogenetic protein-7 (BMP-7) mimics ischemia preconditioning following intestinal ischemia/reperfusion injury in the intestine and liver. 9 38
18461025 2008
50
Expression of bystin in reactive astrocytes induced by ischemia/reperfusion and chemical hypoxia in vitro. 9 38
18929647 2008

Variations for Ischemia

Copy number variations for Ischemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome

Expression for Ischemia

Search GEO for disease gene expression data for Ischemia.

Pathways for Ischemia

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 VEGFA PRKAA2 NOS3 EPO CASP9 CASP3
2 12.6 VEGFA HMOX1 EPO CXCL12 CASP9 CASP3
3
Show member pathways
12.58 NOS3 EGR1 CDK5 CASP9 CASP3
4
Show member pathways
12.56 NOS3 EPO EGR1 CXCL12 CASP9 CASP3
5 11.94 PRKAA2 EGR1 CDK5 CASP3
6 11.9 VEGFA PRKAA2 NOS3 HMOX1
7 11.71 VEGFA NOS3 HMOX1 EPO
8
Show member pathways
11.67 CXCL12 CASP9 CASP3
9
Show member pathways
11.66 NOS3 CASP9 CASP3
10 11.62 VEGFA NOS3 EGR1 CASP3
11 11.56 VEGFA REST GJA1 EGR1 CASP3
12 11.55 NOS3 CASP9 CASP3
13 11.48 VEGFA CASP9 CASP3
14 11.42 VEGFA NOS3 EPO
15 11.38 VEGFA CASP9 CASP3
16 11.27 VEGFA HMOX1 EPO CXCL12
17 11.14 NOS3 HMOX1 GJA1
18 10.99 PRKAA2 NOS3 GJA1 CASP9 CASP3

GO Terms for Ischemia

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.93 NOL3 EGR1 CDK5 CASP9
2 apoptotic process GO:0006915 9.87 NOL3 HMOX1 GJA1 EPO CDK5 CASP9
3 negative regulation of gene expression GO:0010629 9.85 VEGFA REST PRKAA2 GJA1 ACE
4 negative regulation of cell proliferation GO:0008285 9.85 SOD2 REST NOS3 HMOX1 GJA1 ADORA3
5 neuron migration GO:0001764 9.82 GJA1 CXCL12 CDK5
6 response to estradiol GO:0032355 9.82 GJA1 CASP9 CASP3
7 positive regulation of neuron differentiation GO:0045666 9.79 REST EPO CXCL12
8 response to wounding GO:0009611 9.79 CDK5 CASP3 ADORA3
9 response to glucose GO:0009749 9.78 GJA1 EGR1 CASP3
10 regulation of macroautophagy GO:0016241 9.76 PRKAA2 CDK5 CASP3
11 positive regulation of neuron apoptotic process GO:0043525 9.73 CDK5 CASP9 CASP3
12 blood vessel remodeling GO:0001974 9.67 NOS3 NOL3 ACE
13 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.65 VEGFA EPO EGR1
14 induction of positive chemotaxis GO:0050930 9.64 VEGFA CXCL12
15 removal of superoxide radicals GO:0019430 9.63 SOD2 NOS3
16 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.62 SOD2 NOL3
17 response to fluid shear stress GO:0034405 9.6 NOS3 GJA1
18 positive regulation of chemokine biosynthetic process GO:0045080 9.59 HMOX1 EGR1
19 positive regulation of axon extension involved in axon guidance GO:0048842 9.58 VEGFA CXCL12
20 response to cobalt ion GO:0032025 9.57 CASP9 CASP3
21 regulation of blood pressure GO:0008217 9.56 SOD2 NOS3 HMOX1 ACE
22 negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway GO:1903298 9.55 NOL3 HYOU1
23 response to lipopolysaccharide GO:0032496 9.55 NOS3 GJA1 EPO CASP9 CASP3
24 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.54 VEGFA ACE
25 glial cell apoptotic process GO:0034349 9.51 CASP9 CASP3
26 smooth muscle hyperplasia GO:0014806 9.43 NOS3 HMOX1
27 leukocyte apoptotic process GO:0071887 9.4 CASP9 CASP3
28 response to ischemia GO:0002931 9.35 NOL3 HYOU1 GJA1 EGR1 CASP9
29 response to hypoxia GO:0001666 9.23 VEGFA REST NOL3 HMOX1 EPO EGR1
30 negative regulation of apoptotic process GO:0043066 10 VEGFA PRKAA2 NOL3 HYOU1 EPO CASP3

Molecular functions related to Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 death receptor binding GO:0005123 9.16 NOL3 CASP3
2 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 8.96 CASP9 CASP3
3 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 8.62 CASP9 CASP3

Sources for Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....